Clinical and Virologic Outcomes After Changes in First Antiretroviral Regimen at 7 Sites in the Caribbean, Central and South America Network

Abstract

Background HIV-infected persons in lower income countries may experience high rates of antiretroviral therapy (ART) change, particularly due to toxicity or other non-failure reasons. Few reports address patient outcomes after these modifications. Methods HIV-infected adults from 7 Caribbean, Central and South America network (CCASAnet) clinical cohorts who modified > or = 1 drug from first ART regimen (ART-1) for any reason thereby starting a second regimen (ART-2) were included. Results 5,565 ART-naïve HAART initiators started ART-2 after a median of 9.8 months on ART-1; 39% changed to ART-2 due to toxicity and 11% due to failure. Median follow-up after starting ART-2 was 2.9 years; 45% subsequently modified ART-2. Cumulative incidences of death at 1, 3, and 5 years after starting ART-2 were 5.1%, 8.4% and 10.5%, respectively. In adjusted analyses, death was associated with older age, clinical AIDS, lower CD4 at ART-2 start, earlier calendar year, and starting ART-2 because of toxicity (adjusted hazard ratio[aHR]=1.5 vs. failure, 95% confidence interval[CI]=1.0–2.1). Cumulative incidences of VF after 1, 3, and 5 years were 9%, 19%, and 25%. In adjusted analyses, VF was associated with younger age, earlier calendar year, lower CD4 at start of ART-2, and starting ART-2 because of failure (aHR=2.1 vs. toxicity, 95% CI=1.5–2.8). Conclusions Among patients modifying first ART regimen, risks of subsequent modifications, mortality, and virologic failure were high. Access to improved antiretrovirals in the region is needed to improve initial treatment success.

What patient and health facility attributes predict retention and virologic suppression in private for-profit health centers? A retrospective cohort analysis of data from a large private sector antiretroviral treatment program in Nigeria

“…Better health seeking behaviour of women and earlier detection through Prevention of Mother To Child Transmission (PMTCT) interventions may contribute to the observed better outcomes. Low baseline CD4 + counts, use of AZT-based regimens and shorter duration on ART were associated with worse virologic outcomes in this study, consistent with ndings of other researchers in Africa and elsewhere [40][41][42][43][44][45][46][47].…”

A decade of HAART in Latin America: Long term outcomes among the first wave of HIV patients to receive combination therapy

“…Although we did not report the reasons for changes in this population, a previous CCASAnet study with a larger number of ART-naïve patients initiating therapy over a wider time span found that the primary reason for early change was toxicity (57%), whereas treatment failure accounted for early change in only 5% of patients [ 22 ]. Recent CCASAnet data has shown that 61% of those who changed their first regimen changed to a third by 5 years [ 23 ]. Similar findings have been reported elsewhere, even in populations initiating HAART in more recent years [ 24 , 25 ].…”

Effectiveness and Risk Factors for Virological Outcome of Raltegravir-Based Therapy for Treatment-Experienced HIV-Infected Patients

“…Antiretroviral therapy (ART) has changed the evolution of HIV infection, decreasing morbidity and mortality; however, it has some drawbacks [ 1 ]. Virological failure occurs in a significant proportion of patients [ 2 ] and represents one of the most challenging health management issues [ 3 ].…”